The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation.
Süleymanlar
G
G
Department of Nephrology, Akdeniz University Medical School, Antalya, Turkey.
Tuncer
M
M
Sarikaya
M
M
Ersoy
F
F
Aktan
S
S
Yakupoğlu
G
G
Karpuzoğlu
T
T
D000328:Adult; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004359:Drug Therapy, Combination; D005190:Family; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics* / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000191:economics / Q000276:immunology*; D007902:Length of Stay / Q000191:economics; D019520:Living Donors; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis; D014421:Turkey
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid